Rui Xiong

2 papers in the library · 2 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Adverse drug events and toxicological mechanisms of esketamine: a study based on US Food and Drug Administration Adverse Event Reporting System and network toxicology analysis.

Naunyn-Schmiedeberg's Archives of Pharmacology February 26, 2026 Lu Wang, Rui Xiong, Hengxu Liu et al. 1 citation

Esketamine is a novel antidepressant approved by the US Food and Drug Administration (FDA) in 2019, but comprehensive studies on the post-marketing safety evaluation of esketamine across age groups remain limited. The objective of this study is to provide the age-based pharmacovigilance profile of esketamine and the potential toxicological mechanisms, which may provide insights to inform the...

DOI: 10.1007/s00210-026-05108-z Esketamine Humans Antidepressive agents Age factors +7

Increased Kcnq2 in the hippocampal contributes to esketamine-induced long-term cognitive dysfunction in neonatal mice.

Journal of Affective Disorders June 8, 2025 Junjie Zhang, Rui Xiong, Yujuan Su et al. 1 citation

Esketamine is increasingly used to induce general anesthesia in pediatric populations. However, its neurological effects on healthy individuals-especially during early developmental stages-remain a topic of ongoing debate. In particular, concerns persist regarding its impact on the developing brain at extreme ages. Furthermore, the molecular mechanisms underlying these effects have not yet been...

DOI: 10.1016/j.jad.2025.119640 Full text Esketamine Cognitive impairments Kcnq2 Kv7.2 +6